257 related articles for article (PubMed ID: 11004090)
21. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium.
Goffin F; Munaut C; Frankenne F; Perrier D'Hauterive S; Béliard A; Fridman V; Nervo P; Colige A; Foidart JM
Biol Reprod; 2003 Sep; 69(3):976-84. PubMed ID: 12773401
[TBL] [Abstract][Full Text] [Related]
22. Expression and vitamin D-mediated regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in healthy skin and in diabetic foot ulcers.
López-López N; González-Curiel I; Treviño-Santa Cruz MB; Rivas-Santiago B; Trujillo-Paez V; Enciso-Moreno JA; Serrano CJ
Arch Dermatol Res; 2014 Nov; 306(9):809-21. PubMed ID: 25168880
[TBL] [Abstract][Full Text] [Related]
23. Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders.
Abu El-Asrar AM; Van den Steen PE; Al-Amro SA; Missotten L; Opdenakker G; Geboes K
Int Ophthalmol; 2007 Feb; 27(1):11-22. PubMed ID: 17375263
[TBL] [Abstract][Full Text] [Related]
24. Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors.
Latronico T; Mascia C; Pati I; Zuccala P; Mengoni F; Marocco R; Tieghi T; Belvisi V; Lichtner M; Vullo V; Mastroianni CM; Liuzzi GM
Int J Mol Sci; 2016 Mar; 17(4):455. PubMed ID: 27023536
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy.
Abu El-Asrar AM; Mohammad G; Allegaert E; Ahmad A; Siddiquei MM; Alam K; Gikandi PW; De Hertogh G; Opdenakker G
Mol Vis; 2018; 24():394-406. PubMed ID: 29853773
[TBL] [Abstract][Full Text] [Related]
27. Correlations Between MMPs and TIMPs Levels in Aqueous Humor from High Myopia and Cataract Patients.
Jia Y; Hu DN; Sun J; Zhou J
Curr Eye Res; 2017 Apr; 42(4):600-603. PubMed ID: 28402202
[TBL] [Abstract][Full Text] [Related]
28. Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells.
Tarallo S; Beltramo E; Berrone E; Dentelli P; Porta M
Acta Diabetol; 2010 Jun; 47(2):105-11. PubMed ID: 19404565
[TBL] [Abstract][Full Text] [Related]
29. Expression of matrix metalloproteinases and their inhibitors in retinoblastoma.
Adithi M; Nalini V; Kandalam M; Krishnakumar S
J Pediatr Hematol Oncol; 2007 Jun; 29(6):399-405. PubMed ID: 17551402
[TBL] [Abstract][Full Text] [Related]
30. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
31. MMP-TIMP interaction depends on residue 2 in TIMP-4.
Stratmann B; Farr M; Tschesche H
FEBS Lett; 2001 Nov; 507(3):285-7. PubMed ID: 11696356
[TBL] [Abstract][Full Text] [Related]
32. Differential regulation of the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases by cytokines and growth factors in bovine endometrial stromal cells and trophoblast cell line BT-1 in vitro.
Hirata M; Sato T; Tsumagari M; Shimada A; Nakano H; Hashizume K; Ito A
Biol Reprod; 2003 Apr; 68(4):1276-81. PubMed ID: 12606436
[TBL] [Abstract][Full Text] [Related]
33. [Pathomorphology of membranes appearing in proliferative vitreoretinopathies].
Laudańska-Olszewska I; Omulecki W; Dziegielewski K; Pikulski Z; Omulecka A
Klin Oczna; 2006; 108(1-3):28-31. PubMed ID: 16883935
[TBL] [Abstract][Full Text] [Related]
34. Association of functional SNP-1562C>T in MMP9 promoter with proliferative diabetic retinopathy in north Indian type 2 diabetes mellitus patients.
Singh K; Goyal P; Singh M; Deshmukh S; Upadhyay D; Kant S; Agrawal NK; Gupta SK; Singh K
J Diabetes Complications; 2017 Dec; 31(12):1648-1651. PubMed ID: 28964682
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinases and metalloproteinase inhibitors in human interphotoreceptor matrix and vitreous.
Plantner JJ; Smine A; Quinn TA
Curr Eye Res; 1998 Feb; 17(2):132-40. PubMed ID: 9523090
[TBL] [Abstract][Full Text] [Related]
36. Involvement of Matrix Metalloproteinases and their Inhibitors in Bovine Cystic Ovarian Disease.
Peralta MB; Baravalle ME; Belotti EM; Stassi AF; Salvetti NR; Ortega HH; Rey F; Velázquez MML
J Comp Pathol; 2017; 156(2-3):191-201. PubMed ID: 27993358
[TBL] [Abstract][Full Text] [Related]
37. Upregulated expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in BALB/c mouse brain challenged with Japanese encephalitis virus.
Shukla V; Kumar Shakya A; Dhole TN; Misra UK
Neuroimmunomodulation; 2012; 19(4):241-54. PubMed ID: 22441541
[TBL] [Abstract][Full Text] [Related]
38. Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloproteinases of human cardiocytes.
Pan CH; Wen CH; Lin CS
Exp Physiol; 2008 May; 93(5):599-612. PubMed ID: 18296491
[TBL] [Abstract][Full Text] [Related]
39. Ocular TGF-
Saucedo L; Pfister IB; Zandi S; Gerhardt C; Garweg JG
Mediators Inflamm; 2021; 2021():9811361. PubMed ID: 34257518
[TBL] [Abstract][Full Text] [Related]
40. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin.
Massi D; Franchi A; Ketabchi S; Paglierani M; Pimpinelli N; Santucci M
Hum Pathol; 2003 Jan; 34(1):80-8. PubMed ID: 12605370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
